Related Experiment Videos
Experimental tracheal allograft revascularization and transplantation
P R Delaere1, Z Y Liu, R Hermans
1Department of Oto-Rhino-Laryngology Head and Neck Surgery, University Hospitals of Leuven, Belgium.
The Journal of Thoracic and Cardiovascular Surgery
|September 1, 1995
Summary
High-dose cyclosporine (10 mg/kg) effectively prevented rejection in vascularized tracheal allotransplantation. This immunosuppression strategy supports future research into airway wall immunogenicity.
Area of Science:
- Immunology
- Transplantation Surgery
- Regenerative Medicine
Background:
- Tracheal allotransplantation is limited by immune rejection.
- Vascularized grafts with fascial carriers offer potential solutions.
- Optimizing immunosuppression is critical for graft survival.
Purpose of the Study:
- To evaluate the efficacy of varying immunosuppression regimens on tracheal allograft survival.
- To establish a feasible experimental model for tracheal transplantation.
- To investigate the role of cyclosporine and methylprednisolone in preventing graft rejection.
Main Methods:
- Three groups of rats received varying doses of cyclosporine and methylprednisolone post-tracheal allotransplantation.
- A control group received no immunosuppression.
- Graft viability was assessed via silicone dye infusion and histological analysis.
Main Results:
- The control group showed complete graft rejection within 14 days.
- Lower-dose cyclosporine (5 mg/kg) resulted in unpredictable graft survival.
- Combined therapy (cyclosporine and methylprednisolone) led to infection-related necrosis.
- High-dose cyclosporine (10 mg/kg) ensured sustained allograft viability and survival.
Conclusions:
- A daily dose of 10 mg/kg cyclosporine effectively suppresses the immune response in vascularized tracheal allotransplantation.
- This immunosuppression regimen provides a viable model for further airway transplantation studies.
- Further research can now focus on the immunogenicity of the airway wall itself.